ATHENS, Texas, March 15, 2011 /PRNewswire/ — Argon Medical
Devices, Inc. announced today that it has entered into a
definitive license agreement with Rex Medical, LP (“Rex Medical”)
for exclusive global rights to market and distribute the
Option™ Retrievable Inferior Vena Cava Filter, an implantable
device used in the prevention of Pulmonary Embolism (PE).
“We are very pleased with the addition of Option™ to our
product portfolio. This proven technology has rapidly become a
leader in this disease segment due both to its efficacy and safety,
and we are confident it will prove to be the preferred device of
its kind,” said George A. Leondis, President of Argon Medical
Devices, Inc. “This partnership provides a compelling strategic
opportunity for Argon, allowing us to provide our customers with
another best in class product in the Interventional arena.”
“Rex Medical is looking forward to again collaborating with
Argon, on this innovative and pivotal technology,” commented
Lindsay L. Carter, President of Rex Medical, LP. “Argon’s
focused commitment to its customer base, coupled with its global
sales and marketing presence and corresponding operational
capabilities, make it the ideal partner.”
Argon will be exhibiting at the 36th Annual Society of
Interventional Radiology (SIR) Scientific Meeting, to be held in
Chicago, IL from March 27-30, 2011.
About the Option™ Inferior Vena Cava Filter
The nitinol, Option™ IVC Filter, with a low profile 5Fr
(6.5Fr O.D.) delivery system, is designed to be implanted into the
inferior vena cava of patients to prevent recurrent PE. The filter
is designed with symmetric flared struts to direct clot volume into
the center of the vessel for maximum dissolution and preservation
of blood flow allowing for capture of clinically significant clot
and protection against PE. Designed as both a permanent or
retrievable implant, thi
‘/>”/>
SOURCE